Phase 2 Oesophageal Cancer Trial, Recruiting NCT06410651 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06410651
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a specific type of esophageal cancer called squamous cell carcinoma, confirmed by a tissue sample (biopsy)
  • After receiving 2 to 4 rounds of initial chemotherapy (with or without immunotherapy), your cancer either stayed the same, grew only in the nearby area, or was considered by surgeons to be unable to be removed with surgery — and has not spread to distant parts of the body
  • You are generally able to carry out normal daily activities (measured by a standard health score of 70 or above)
  • Your blood counts and organ function are within acceptable ranges, meaning your blood, liver, and kidneys are working well enough (confirm with trial site for exact values)

Who may not be able to join:

  • You have been diagnosed with another type of cancer in addition to esophageal cancer — with the exception of certain fully treated skin cancers or early-stage cervical cancer that has been cured
  • At the time of your diagnosis, the cancer had already spread to distant parts of the body, such as bones, brain, lungs, liver, or caused fluid build-up around the lungs or abdomen
  • You currently have an active infection, such as active tuberculosis or active hepatitis
  • You have a medical reason why you cannot receive targeted therapy (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13311583220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 March 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

R0 resection rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov